The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...
Sanofi invests in Enveda, reaffirming the industry’s confidence in its AI drug discovery platform and ability to deliver differentiated medicines.
While many drug companies avoid targets deemed ‘undruggable’, US-based Enveda Biosciences attacks them head on. Founded in 2019, Enveda uses unique libraries and machine-learning technologies ...
Sanofi is in the final stages of selling its European generics business, Zentiva, to private equity firm Advent International. The companies have signed a share purchase agreement valued at €1.9 ...
Enveda, a biotechnology company using AI to translate nature into new medicines, is proud to announce testing of its lead asset, ENV-294, in a second indication: asthma. This novel therapeutic ...